If you are searching for Foundayo NHS availability, the position on 10 October 2026 is this: Foundayo (orforglipron) is licensed in the UK but not available on the NHS. The National Institute for Health and Care Excellence (NICE) is still appraising it: its committee met in July and asked the manufacturer for more evidence, a second meeting is scheduled for 10 November 2026, and guidance is provisionally expected on 27 January 2027. Until NICE recommends it, it is not routinely available on the NHS, so in practice a private prescription is the only route.

Everything below comes from NICE, the MHRA, NHS England and the devolved nations' medicines bodies, checked on the date above. It is information, not medical advice: Foundayo is a prescription-only medicine, and a qualified prescriber decides whether it is suitable.

Key takeaway: "licensed" and "on the NHS" are two different gates. The MHRA opened the first on 10 August 2026; the second is NICE appraisal ID6516, with publication provisionally expected on 27 January 2027. A positive decision would almost certainly come with eligibility rules, and possibly a staged roll-out, as for the weight-loss injections.

Foundayo NHS availability: what NICE's page says today

NICE lists "Orforglipron for managing overweight and obesity [ID6516]", reference GID-TA11650, status "In progress", under its standard single technology appraisal process. The suggested remit is "to appraise the clinical and cost effectiveness of orforglipron within its marketing authorisation for managing obesity or overweight with at least one weight-related co-morbidity".

The timeline runs from topic selection in November 2024 to a committee meeting on 14 July 2026. A note added on 5 August 2026 records that the committee "was unable to reach a full conclusion because more information is needed from the company", which "will be asked to submit additional evidence" for a further meeting. The provisional schedule names 10 November 2026 and 27 January 2027. None of this is a verdict: NICE has published no draft recommendation for or against Foundayo. Our UK availability page keeps the headline status current.

How a NICE appraisal works, step by step

  • Scope and evidence. NICE defines the question, the company submits evidence, and an independent academic group (here, PenTAG at the University of Exeter) reviews it.
  • Committee meeting. An independent committee weighs the evidence and hears clinical and patient experts, in public.
  • Draft guidance. If the committee does not recommend the medicine, or recommends it more narrowly than its licence, it issues draft guidance for a four-week consultation, then meets again.
  • Final draft guidance, which consultees can appeal within 15 days, then final guidance.

Then the funding rule applies. NICE says the NHS "is legally obliged to fund and resource medicines and other treatments recommended by our TAs", and its guidance puts the period at "ordinarily" within three months of final publication. NICE can set a longer period where services or staff are not in place, and NHS England can ask for one when the expected budget impact is large.

What a "yes" would, and would not, mean

A recommendation would make Foundayo an NHS option for the people it names, not for everyone with a licence-eligible BMI. NICE's manual calls this an "optimised recommendation". The two weight-loss injections show what it means in practice.

  • Semaglutide (Wegovy), TA875, March 2023: recommended only for a maximum of two years, within a specialist weight management service, for adults with at least one weight-related condition and a BMI of 35 or more (or 30 to 34.9 if they meet referral criteria), with lower thresholds for some ethnic backgrounds.
  • Tirzepatide (Mounjaro), TA1026, December 2024: recommended for adults with a BMI of 35 or more and at least one weight-related condition, usable in primary care, but with a funding variation. NHS England's interim commissioning guidance phases it in over three years and counts five named conditions (high blood pressure, abnormal blood fats, obstructive sleep apnoea, cardiovascular disease, type 2 diabetes): first a BMI of 40 or more with four or more of them, then from around June 2026 a BMI of 35 to 39.9 with four or more. NHS England's case for the variation, which NICE accepted, included that weight management services "are not routinely commissioned in primary care".

So a positive decision would not, by itself, mean a GP can prescribe Foundayo to anyone who asks. It would mean funding for a defined group, in a defined setting, on a timetable that depends on whether NHS England seeks a similar variation. Both injection appraisals also include a six-month review point. Nothing is known until NICE publishes.

Scotland, Wales and Northern Ireland

  • Scotland: a medicine "has to be accepted for use by SMC", the Scottish Medicines Consortium, before routine prescribing; it had published no advice on orforglipron as of 10 October 2026.
  • Wales: the All Wales Therapeutics and Toxicology Centre says NICE's guidance "applies in England and Wales", with health boards usually expected to make a recommended medicine available within 60 days of NICE's final draft guidance.
  • Northern Ireland: the Department of Health runs its own process for endorsing NICE technology appraisals.

What about type 2 diabetes?

The UK licence also covers type 2 diabetes, but there is no NICE appraisal for that use. NICE's topic-selection record of 10 April 2025 says a separate evaluation was not selected because its type 2 diabetes guideline (NG28) covers GLP-1 receptor agonists "at a class level". How that applies to orforglipron is a question for NICE and local formularies.

The only route today: a private prescription

Lilly made Foundayo available to UK private prescribers on 24 August 2026. A prescriber must judge whether it is clinically appropriate, and may decide it is not; the licensed uses and dose steps are the same whoever pays. Private prices vary between regulated providers, and this site names no providers and quotes no figures.

Foundayo is a black-triangle medicine under additional monitoring, so the MHRA asks for every suspected side effect to be reported through the Yellow Card scheme. Our side effects page covers what the trials and UK leaflet report; our trial results summary covers the evidence NICE's committee is weighing.

What could move the date

NICE calls 27 January 2027 an expected date, and the schedule has already stretched once. After 10 November 2026 NICE may consult on draft guidance, pushing final guidance later, or go straight to final draft guidance; an appeal adds time, and a funding variation would stage roll-out after publication. Our UK availability page and FAQ follow NICE's project page.

Frequently asked questions

Is Foundayo available on the NHS now?

No. As of 10 October 2026 Foundayo (orforglipron) is licensed by the MHRA but not available on the NHS. NICE's appraisal (ID6516) is in progress, and the MHRA said decisions on NHS use would follow an evaluation by NICE.

When will NICE decide on Foundayo?

NICE's page gives an expected publication date of 27 January 2027, with a second committee meeting scheduled for 10 November 2026. Both dates are provisional and can move, for example if draft guidance goes out to consultation.

If NICE says yes, will a GP be able to prescribe it straight away?

Not necessarily. NICE recommendations usually apply to a defined group and setting, and the NHS normally has three months to fund them. For tirzepatide NICE granted a funding variation and access was phased over three years; something similar is possible here.

Will Foundayo be on the NHS in Scotland, Wales and Northern Ireland?

Each nation has its own route. Scotland needs Scottish Medicines Consortium acceptance, and it had published no advice on orforglipron as of 10 October 2026. NICE guidance applies in Wales, usually within 60 days of final draft guidance. Northern Ireland's Department of Health endorses NICE appraisals through its own process.

Is this article medical advice?

No. It is general information about the UK approval and funding process. Foundayo is a prescription-only medicine, and a qualified prescriber decides whether it is suitable; private prices vary between regulated providers, and this site does not name providers or quote prices.

Sources

  1. NICE. Orforglipron for managing overweight and obesity [ID6516], GID-TA11650 (checked 10 October 2026). nice.org.uk
  2. NICE. About technology appraisal guidance. nice.org.uk
  3. NICE. TA1026 Tirzepatide and TA875 Semaglutide for managing overweight and obesity. nice.org.uk
  4. NHS England. Interim commissioning guidance: TA1026 and the NICE funding variation for tirzepatide. england.nhs.uk
  5. NICE. Orforglipron for treating type 2 diabetes [TSID12130] — topic prioritisation decision, 10 April 2025. nice.org.uk
  6. MHRA. UK first in Europe to authorise orforglipron, 10 August 2026. gov.uk
  7. Foundayo — Summary of Product Characteristics. emc. medicines.org.uk
  8. Scottish Medicines Consortium, About us (scottishmedicines.org.uk); AWTTC, How medicines are approved for use in NHS Wales (awttc.nhs.wales); Department of Health (NI), NICE Technology Appraisals (health-ni.gov.uk).

Related reading